Our GI Therapeutic Expertise
For more than 30 years, Alimentiv has designed and delivered unparalleled GI trials with our deep scientific and medical expertise, track record of operational excellence, and a global footprint. Our teams bring clarity to complex trials so your program moves forward with confidence.
With a track record supporting more than 70% of IBD compounds in development, we know what it takes to advance GI therapies with precision and quality.
Our GI-specialized therapeutic expertise includes:
- Inflammatory bowel disease (IBD): Ulcerative colitis (UC), Crohn’s disease (CD), fibrostenosing Crohn’s disease, pouchitis
- Eosinophilic gastrointestinal diseases (EGIDs): Eosinophilic esophagitis (EoE)
- Microscopic colitis
- Celiac disease (CeD)
- Functional and motility disorders of the gastrointestinal tract: Gastroparesis
- Familial adenomatous polyposis (FAP)
- Inflammatory liver conditions: Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC)
The Secret to GI Trial Success
Successful GI trials rely on alignment between medical expertise, clinical operations, imaging, and data oversight — exactly what Alimentiv delivers.
We support the delivery of reliable and timely outcomes in a cost-effective manner with:
Scientific and Medical Leaders
GI medical and scientific experts shape protocols, endpoints, and central reading strategies, drawing on a global KOL network
Innovative Protocol Design
Feasible designs that address your research questions, informed by KOLs, patient advocacy groups, and Alimentiv’s decades of operational experience
Expert Imaging Solutions and Central Reading
Purpose-built technologies/platforms ensure standardized imaging acquisition and expert central reading across endoscopy, histopathology, magnetic resonance enterography (MRE), and intestinal ultrasound (IUS)
End-to-End Services
Integrated services including, but not limited to:
- Clinical operations
- Project and site management
- Centralized imaging
- Medical writing
- Safety management
- Medical monitoring
- Biomarker analysis
- Biostatistics
- Data science
- Regulatory strategy
Moving GI Research Forward
Our expert contributions to the GI therapeutic focus area include peer-reviewed publications, development and validation of novel outcome measures, and scoring methodologies including PROs and leading-edge medical imaging approaches widely adopted in GI clinical research.
Frequently Asked Questions
Alimentiv specializes in gastrointestinal therapeutic indications including inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal diseases (EGIDs), gastroparesis, and functional and motility disorders of the GI tract.
Our exclusive focus on gastrointestinal clinical trials means deeper expertise in GI endpoints, gold standard imaging assessments, and site networks experienced in the GI patient population. We have supported >70% of IBD compounds — many of which are available to patients today — and maintain a global network of GI key opinion leaders worldwide. This specialization translates to faster enrollment and higher data quality.
Alimentiv provides centralized imaging reading services across all major GI modalities: endoscopy (via CIMS®), histopathology (via Lucidity™), MR enterography (MRE), and intestinal ultrasound (IUS) through our partnership with the International Bowel Ultrasound (IBUS) Group. Our purpose-built platforms ensure standardized acquisition, expert central reading, and AI-assisted analysis where appropriate.
